Evidence map›Paper›PMID 37751078›Full record

ArticleBreast cancer research and treatment2024

Discordance of Oncotype DX scores in synchronous bilateral and unilateral multifocal breast cancers.

Jing Wang, Hui Chen, Jenna Koenig, Yun Wu, Isabelle Bedrosian, Banu Arun, Qingqing Ding, Laila Khazai, Erika Resetkova, Lei Huo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jing WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hui Chen *Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hchen7@mdanderson.org.ORCID http://orcid.org/0000-0002-5847-0561
Jenna KoenigDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yun WuDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Isabelle BedrosianDepartment of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Banu ArunDepartment of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Qingqing DingDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laila KhazaiDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Erika ResetkovaDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lei HuoDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nour SneigeDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Constance AlbarracinDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. calbarra@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOncotype DX, a 21-gene expression profiling test, has become standard of care in the management of estrogen receptor (ER)-positive breast cancer. In multifocal tumors, it is unclear whether testing of the different foci is necessary. We evaluated the concordance of Oncotype DX recurrence scores (RS) between 2 tumor foci in synchronous bilateral or unilateral multifocal tumors and characterized pathological predictors of discordance.

methodsWe reviewed 713 ER+, HER2- primary invasive breast cancer patients with Oncotype RS and identified 17 bilateral synchronous patients (34 tumors) and 13 unilateral multifocal patients (26 tumors) with available Oncotype RS on all foci. Discordance in Oncotype RS between synchronous tumors was recorded and associations with clinicopathologic features including tumor size, histology, Nottingham histologic grade, progesterone receptor staining, and Ki67 index were analyzed.

resultsBilateral synchronous tumors were present in older patients (median age 59 years) and had larger tumor (median size 17 mm) and more discordant histology (10/17, 59%) as compared to unilateral multifocal tumors (median age 49 years, p < 0.01; median tumor size 12 mm, p = 0.01; discordant histology 2/13, 15%, p = 0.03). Oncotype RS were discordant in 47% (8/17) of bilateral and 54% (7/13) of unilateral multifocal tumors. Concordant Oncotype RS was associated with similar histologic grade and Ki67 index in 78% (7/9) of bilateral and 100% (6/6) of multifocal tumors. In contrast, only 25% (2/8) of bilateral (p = 0.06) and 14% (1/7) of unilateral multifocal (p < 0.01) cases with discordant Oncotype RS had concordant histology grades and Ki67 levels. In synchronous tumors with discordant Oncotype RS and Ki67 index, all (4/4) foci with higher RS had higher Ki67 index.

conclusionDiscordance of Oncotype RS is common in both bilateral and unilateral multifocal breast cancer and is likely associated with discordant histologic grade or Ki67.

Indexed as

Breast NeoplasmsNeoplasms, Multiple PrimaryUnilateral Breast NeoplasmsAgedBiomarkers, TumorFemaleGene Expression ProfilingHumansKi-67 AntigenMiddle AgedNeoplasm Recurrence, LocalPrognosisBiomarkers, TumorKi-67 AntigenBilateral breast cancerBreast cancerKi67Multifocal breast cancerOncotype DX testRecurrence score

Identifiers

PMID37751078
OpenAlexW4387033275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.